Successfully applied drugs targeting BCR‐ABL1 fusion in hematological malignancy ALK fusion in NSCLC, have dramatically ignited enthusiasm for deep exploration of the landscape of gene fusions (Mertens et al., 2015). Here, BCR is linked to non-small cell lung carcinoma.